{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-001879","form_type":"8-K","ticker":"ACH","cik":"0000075252","company_name":"ACCENDRA HEALTH INC/VA/","filed_at":"2025-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.273682+00:00","generated_at":"2026-05-26T00:41:23.383156+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Owens & Minor reports Q4 GAAP net loss $296M, adjusted EPS $0.55; exploring sale of P&HS segment","bullets":["Q4 GAAP net loss $296M ($3.84 loss per share); adjusted net income $43M ($0.55 EPS).","Total revenue $2,696M in Q4, $10,701M for FY2024; adjusted EBITDA $138M Q4, $523M FY.","Company actively engaging in discussions for potential sale of Products & Healthcare Services segment.","Board authorized share repurchase program up to $100 million; also reduced debt $244M in 2024.","2025 guidance midpoint expects double-digit adjusted EBITDA and adjusted EPS growth, improving cash flow."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-001879","json":"https://secwatch.observer/filing/0001558370-25-001879.json","markdown":"https://secwatch.observer/filing/0001558370-25-001879.md","text":"https://secwatch.observer/filing/0001558370-25-001879.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/75252/000155837025001879/0001558370-25-001879-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/75252/000155837025001879/omi-20250228x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T00:41:23.383156+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}